Novavax, Inc. NVAX
10.60 USD +0.82 (+8.38%)
Nov 6, 2026, 1:09 PM EST
10.00 Day range 10.90
6.20 52-week range 13.39
- YTD
- +57.74%
- 1 year
- +39.66%
- Market cap
- 1.75B
- Revenue (ttm)
- 413.80M
- Profit margin
- -59.87%
- EPS (ttm)
- -1.58
- Shares out
- 164.95M
- Forward P/E
- -64.97
- YTD return
- +57.74%
- 1-year return
- +39.66%
- Volume
- 3.51M
- Avg volume
- 6.44M
- Open
- 10.06
- Previous close
- 9.78
- Day's range
- 10.00 – 10.90
- 52-week range
- 6.20 – 13.39
- Beta
- 2.72
- Analysts
- Buy
- Price target
- 14.44 (+36.3%)
- Earnings date
- Feb 25, 2027
5D +0.38 (+3.71%)
Key statistics
- Enterprise value
- 1.17B
- PEG ratio
- 1.32
- Price / sales
- 4.25
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- -76.30%
- Free cash flow
- 153.39M
- Total cash
- 719.34M
- Total debt
- 297.32M
- Return on equity
- 0.00%
- Short % of float
- 28.89%
- 50-day average
- 10.49
- 200-day average
- 9.31
Analyst view
Consensus: buy
Buy
Price target (mean) 14.44 +36.3% upside
Now 10.60
- Target (low)
- 7.00
- Target (mean)
- 14.44
- Target (high)
- 25.00
Ratings (0m) 9 5 buy · 1 hold · 3 sell
- Strong buy0
- Buy5
- Hold1
- Sell1
- Strong sell2
Next earnings
Feb 25, 2027
Expected Feb 25, 2027. Consensus EPS estimate -0.42.
Financials — quick view
NVAX Revenue — quarterly 56.70M
NVAX Net income — quarterly -53.39M
NVAX EPS — quarterly -0.32
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 25, 2027 | Dec 30, 2026 | 0.07102 | — | — | — |
| Nov 5, 2026 | Sep 30, 2026 | -0.34595 | -0.19 | +0.16 | +45.08% |
| Aug 6, 2026 | Jun 30, 2026 | -0.37984 | -0.32 | +0.06 | +15.75% |
| May 6, 2026 | Mar 31, 2026 | -0.25 | -0.06 | +0.19 | +76.00% |
| Feb 26, 2026 | Dec 31, 2025 | -0.66 | 0.11 | +0.77 | +116.67% |
| Nov 6, 2025 | Sep 30, 2025 | -1.08 | -1.25 | -0.17 | -15.74% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 15, 2026 | Citigroup | main | Sell | Sell |
| Jun 11, 2026 | BTIG | reit | Buy | Buy |
| May 6, 2026 | TD Cowen | main | Hold | Hold |
| Feb 27, 2026 | HC Wainwright & Co. | main | Buy | Buy |
| Jan 20, 2026 | BTIG | reit | Buy | Buy |
| Nov 18, 2025 | JP Morgan | main | Underweight | Underweight |
About Novavax, Inc.
Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally. The company commercializes Nuvaxovid, a COVID-19 vaccine; and R21 Matrix-M adjuvant malaria vaccine. It has license and collaboration agreements with Sanofi, Pfizer Inc., Takeda Pharmaceutical Company Limited, and Serum Life Sciences Limited for the to develop, manufacture, and commercialize the COVID-19 vaccine. The company was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- novavax.com
News
B. Riley Securities Reiterates Buy on Novavax, Lowers Price Target to $16 
Novavax Q3 Earnings Call Highlights 
Novavax (NVAX) Reports Q3 Loss, Tops Revenue Estimates 
Novavax Raises FY2026 Sales Guidance from $235.000M-$275.000M to $385.000M-$415.000M vs $380.285M Est 
Novavax Reports Third Quarter 2026 Financial Results and Operational Highlights 
Novavax Earns $125M Milestone Payment With Initiation Of Sanofi's Phase 3 Influence-COVID-19 Combination Vaccine Study Through Nuvaxovid 
Novavax's Second-Largest Shareholder Sells $32.6 Million in Stock, Ends Activist Push 
Citigroup Maintains Sell on Novavax, Raises Price Target to $8 
Stephen King Slams Trump’s New Press Secretary as Past Vaccine Conspiracy Theories, Third-Term Posts Spark Fresh Controversy: 'She Appears to Have Tried to…' 
A New War on Cancer? NIH's Vaccine Initiative Sparks Biotech Stock Rally
Your note
Sign in to keep a note on NVAX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ALTON GREGG H | Director | Conversion of Exercise of derivative security | Jun 17, 2026 | 47,685 |
| CASEY MARK J | Officer | Conversion of Exercise of derivative security | Mar 2, 2026 | 90,067 |
| DOUGLAS RICHARD H | Director | Conversion of Exercise of derivative security | Jun 17, 2026 | 73,220 |
| JACOBS JOHN C | Chief Executive Officer | Conversion of Exercise of derivative security | Mar 2, 2026 | 225,680 |
| KELLY JAMES PATRICK | Chief Financial Officer | Conversion of Exercise of derivative security | Mar 5, 2026 | 130,599 |
| MOTT DAVID M | Director | Conversion of Exercise of derivative security | Jun 17, 2026 | 79,770 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 8.46% | 13,946,881 | 148.53M | Jun 29, 2026 |
| Shah Capital Management | 7.38% | 12,173,481 | 129.65M | Sep 29, 2026 |
| State Street Corporation | 7.12% | 11,740,550 | 125.04M | Jun 29, 2026 |
| Vanguard Portfolio Management LLC | 4.61% | 7,607,996 | 81.03M | Jun 29, 2026 |
| Vanguard Capital Management LLC | 4.40% | 7,257,449 | 77.29M | Jun 29, 2026 |
| Sanofi | 4.17% | 6,880,481 | 73.28M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.15% | 5,197,170 | 55.35M | Jun 29, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 2.79% | 4,603,628 | 49.03M | Sep 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.41% | 3,971,987 | 42.30M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 2.28% | 3,766,470 | 40.11M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Growth Index Fund | 1.31% | 2,163,104 | 23.04M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 1.15% | 1,893,260 | 20.16M | Jun 29, 2026 |